TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1593552
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of normal saline alone
Study: 27290652
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (450 mg/day)
Study: 19931895
Drug: fesoterodine 4
Normalized name: fesoterodine 4 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: fesoterodine 4 mg or 8 mg once daily
Study: 15642030
Drug: Mechanical debridement
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical debridement using plastic curettes and antiseptic therapy with chlorhexidine digluconate (0.2%) (C)
Study: 12065466
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg melatonin daily for 6 months
Study: 760732
Drug: Chlorpropamide tablet
Normalized name: Chlorpropamide Tablets
DrugBank: Chlorpropamide (DB00672)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpropamide tablet formulations
Study: 760732
Drug: Chlorpropamide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpropamide (all formulations)
Study: 28116765
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment with 600 mg/d α-lipoic acid intravenously (α-LA group)
Study: 28116765
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (DM group)
Study: 25537278
Drug: TARGET 1®
Approvals — FDA: no, EMA: no, PMDA: no
Description: TARGET 1® (active formulation)
Study: 19255334
Drug: Maintenance rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance rituximab (MR) 375 mg/m² once per week for 4 weeks every 6 months for 2 years
Study: 11584994
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for primary and secondary prevention of toxoplasmosis
Study: 2955672
Drug: Doxazosin (DOX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (DOX), 10.8 mg daily
Study: 2955672
Drug: Hydrochlorothiazide (HCTZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ), 89.1 mg daily
Study: 26614120
Drug: Insulin stimulation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin stimulation after acute exercise
Study: 23772874
Drug: Midazolam (CYP3A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (CYP3A probe) administered to patients with severe liver cirrhosis (CP C)
Study: 23772874
Drug: Midazolam (CYP3A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (CYP3A probe) administered to patients with moderate liver cirrhosis (CP B)
Study: 21883386
Drug: Domperidone 10mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 10mg, four doses daily, at 4h intervals
Study: 21883386
Drug: Ketoconazole 200mg
Normalized name: KETOCONAZOLE 200MG TAB
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole 200mg 12‐hourly
Study: 21189775
Drug: Schwarz appliance
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz appliance treatment (expanded group)
Study: 15983525
Drug: Walnut-specific (modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut-specific (modified low fat including 30 g walnuts/day)
Study: 12463724
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) administration of almotriptan (3 mg)
Study: 12463724
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) administration of almotriptan (6 mg)
Study: 12463724
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of almotriptan (25 mg)
Study: 7540696
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 micrograms/kg body weight per day)
Study: 30674486
Drug: Community randomised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community randomised trial intervention to improve school hearing screening and referral process, details on dosage and duration not specified.
Study: 26181658
Drug: Fedratinib 400
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fedratinib 400 mg
Study: 26181658
Drug: Fedratinib 500
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fedratinib 500 mg
Study: 17243195
Drug: OD1 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: OD1 (20 mg once daily with a 1-step up-titration)
Study: 17243195
Drug: OD3 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: OD3 (20 mg once daily with a 3-step up-titration)
Study: 17243195
Drug: BID3 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID3 (10 mg twice daily with a 3-step up-titration)
Study: 15071282
Drug: Virosome-adjuvanted influenza
Normalized name: Influenza, adjuvanted, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosome-adjuvanted influenza vaccine
Study: 15071282
Drug: Split influenza
Normalized name: INFLUENZA VIRUS (SPLIT) VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split influenza vaccine
Study: 9629991
Drug: Ranid (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranid (300 mg)
Study: 9629991
Drug: Zantac (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zantac (300 mg)
Study: 8159781
Drug: Cerebrolysin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin (30 ml in 100 ml physiological saline i.v. once a day from Monday to Friday for four weeks)
Study: 8159781
Drug: Placebo (130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (130 ml physiological saline)
Study: 26577969
Drug: Camel milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camel milk therapy for 2 weeks
Study: 14979753
Drug: Intervening treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervening treatment with varying number of memory retrievals
Study: 14979753
Drug: Intervening treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervening treatment with time allowed for memory retrievals
Study: 11681505
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with mitomycin-C (0.4 mg/ml for 2.5 min)
Study: 9444745
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole (100 mg followed by 50 mg/day for 14 days) with catheter replacement
Study: 30616613
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral polyherbal dietary supplement (GlucoSupreme™ Herbal) for 12 weeks
Study: 19568715
Drug: TXYF granule,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXYF granule, one package twice a day for 4 weeks
Study: 19568715
Drug: Miyarisan, two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miyarisan, two tablets three times a day for 4 weeks
Study: 9697724
Drug: Nonoxynol-9 (N-9)
Normalized name: Nonoxynol 9
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoxynol-9 (N-9) gel applied daily for 2 weeks
Study: 3176107
Drug: Standard one‐compartmental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard one‐compartmental model calculations after a single dose of theophylline syrup (mean dose 413 mg)
Study: 3176107
Drug: Low theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low theophylline dosage regimen (twice daily)
Study: 3176107
Drug: Medium theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium theophylline dosage regimen (twice daily)
Study: 3176107
Drug: High theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High theophylline dosage regimen (twice daily)
Study: 3176107
Drug: Drug nomogram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug nomogram
Study: 25733274
Drug: Finasteride (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (3 years treatment)
Study: 23742033
Drug: Short-course radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course radiotherapy (5 Gy x 5) followed by full-dose chemotherapy (capecitabine and oxaliplatin) in 6 cycles before surgery
Study: 23742033
Drug: Standard arm:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard arm: chemoradiation (1.8 Gy x 25 or 2 Gy x 25 with capecitabine) preoperatively, followed by selective postoperative adjuvant chemotherapy (optional)
Study: 21967987
Drug: Dopamine D(2/3)
Normalized name: dopamine hydrochloride 3.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D(2/3) receptor agonist (pramipexole, 0.5 mg)
Study: 21967987
Drug: Dopamine D(2/3)
Normalized name: dopamine hydrochloride 3.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D(2/3) receptor antagonist (amisulpride, 400 mg)
Study: 16390899
Drug: Quality improvement
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quality improvement program (medication)
Study: 16390899
Drug: Quality improvement
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quality improvement program (therapy)
Study: 16390899
Drug: Quality improvement
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quality improvement program (medication/therapy)
Study: 14657758
Drug: NVP given
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP given OW (4 mg/kg from birth to 14 days, upward arrow to 8 mg/kg from 15 days to 24 weeks)
Study: 14657758
Drug: NVP given
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP given TW (4 mg/kg from birth to 14 days, upward arrow to 8 mg/kg from 15 days to 24 weeks)
Study: 14657758
Drug: NVP given
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP given OD (2 mg/kg from birth to 14 days, upward arrow to 4 mg/kg from 15 days to 24 weeks)
Study: 10992173
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg 17beta‐estradiol + 25 microg gestodene (group 2/25s)
Study: 10992173
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol + 50 microg gestodene (group 2/50s)
Study: 10992173
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol + 25 microg gestodene (group 1/25s)
Study: 10992173
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol + 25 mg gestodene (group 1/25c)
Study: 24356749
Drug: Glibenclamide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide treatment for 48 weeks
Study: 22104012
Drug: Medication plus
Normalized name: salicylic acid Medicated Shampoo [Ionil Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication plus Deep Brain Stimulation (ODT + DBS)
Study: 21939467
Drug: Optimal Drug
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Drug Therapy (ODT)
Study: 20339970
Drug: Nesiritide (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nesiritide (loading dose 0.5 microg/kg, maintenance dose 0.0075 microg/kg/min)
Study: 15820796
Drug: Midluteally started
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Midluteally started triptorelin administration continued until the first day of hMG treatment (group S)
Study: 15820796
Drug: Midluteally started
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Midluteally started triptorelin administration continued up to and including the fourth day of hMG treatment (group M)
Study: 15820796
Drug: Midluteally started
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Midluteally started triptorelin administration continued until the day of hCG injection (group L)
Study: 1320740
Drug: Formalin-inactivated hepatitis
Normalized name: formalin
DrugBank: Formaldehyde (DB03843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formalin-inactivated hepatitis A vaccine
Study: 15871638
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (0.25 g twice daily)
Study: 11953727
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (I‐NO) at doses of 5, 20, and 80 ppm
Study: 11153578
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP), 800 microg daily for 3 months
Study: 1433876
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 5 micrograms.kg‐1
Study: 3893208
Drug: Epidural pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural pethidine 50 mg
Study: 3893208
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine 25 mg
Study: 3893208
Drug: Epidural pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural pethidine 50 mg and Epidural bupivacaine 25 mg
Study: 25207547
Drug: Test tablet
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test tablet (ambroxol 30 mg)
Study: 25207547
Drug: Test capsule
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test capsule (ambroxol 30 mg)
Study: 25207547
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (ambroxol 30 mg)
Study: 24617028
Drug: Intensive lifestyle
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive lifestyle intervention (monthly consultations with primary care physician, weekly nutrition counseling for first 3 months, then monthly, and 12 group sessions in behavioral change protocol)
Study: 24617028
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (monthly consultations with primary care physician)
Study: 18052950
Drug: Topiramate 25
Normalized name: topiramate 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 25 mg per day
Study: 16214437
Drug: GIK infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIK infusion (25% glucose, 50 IU of soluble insulin per liter, and 80 mmol of potassium chloride per liter at 1 ml/kg/hour over 24 hours)
Study: 12404671
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract EGb 761 (180 mg/day)
Study: 10096258
Drug: Enoxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin (400 mg twice a day)
Study: 26323511
Drug: Intramuscular Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular Haloperidol
Study: 26323511
Drug: Intramuscular Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular Midazolam
Study: 23721797
Drug: Exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise program focusing on muscle strength and daily activities only (Control)
Study: 21784190
Drug: Eldecalcitol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eldecalcitol (0.75 μg daily)
Study: 14996859
Drug: Mastectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mastectomy with chemotherapy
Study: 14996859
Drug: Mastectomy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mastectomy without chemotherapy
Study: 14996859
Drug: Lumpectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumpectomy with chemotherapy
Study: 14996859
Drug: Lumpectomy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumpectomy without chemotherapy
Study: 11318765
Drug: Ondansetron (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (16 mg i.v.)
Study: 3360055
Drug: Trazodone (controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (controlled-release formulation)
Study: 3360055
Drug: Trazodone (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (conventional formulation)
Study: 25896965
Drug: 200mg mifepristone
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg mifepristone followed by 400 μg buccal misoprostol every 3 hours until complete fetal and placental expulsion (maximum 10 doses)
Study: 25896965
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by 400 μg buccal misoprostol every 3 hours until complete fetal and placental expulsion (maximum 10 doses)
Study: 25896965
Drug: 200mg mifepristone
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg mifepristone followed by 400 μg buccal misoprostol
Study: 25896965
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by 400 μg buccal misoprostol
Study: 20684442
Drug: Visible dental
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Visible dental decay (twice the amount of decay)
Study: 19052336
Drug: Treated nets
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treated nets (lambdacyhalothrin 2.5 CS at 10 mg (a.i.)/m(2))
Study: 11075307
Drug: Inhaled cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled cyclosporin A (ADI628) 10 mg single dose
Study: 11075307
Drug: Inhaled cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled cyclosporin A (ADI628) 20 mg dose group
Study: 11075307
Drug: Inhaled cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled cyclosporin A (ADI628) 10 mg bid (highest steady-state dose)
Study: 11075307
Drug: Repeated inhaled
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated inhaled doses of ADI628
Study: 11075307
Drug: Oral cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclosporin A (3 mg/kg)
Study: 6839003
Drug: Theobid (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theobid (260 mg)
Study: 6839003
Drug: Theo-Dur (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theo-Dur (200 mg)
Study: 6839003
Drug: Choledyl (128
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choledyl (128 mg)
Study: 31635890
Drug: Riluzole oral
Normalized name: riluzole Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole oral suspension 50 mg/10 mL via nasogastric tube
Study: 31635890
Drug: Riluzole oral
Normalized name: riluzole Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole oral suspension 50 mg/10 mL orally
Study: 30630793
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of methotrexate and immune adsorption
Study: 26511959
Drug: Praziquantel (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (total dose 60 mg/kg given as two split doses)
Study: 18926131
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation and exercise (800 mg calcium supplementation and 1-hour cycling bout per day at 65%-70% of heart rate reserve)
Study: 12621132
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg per day
Study: 10554512
Drug: Home i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home i.v. treatment (HIT)
Study: 10554512
Drug: In-patient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-patient treatment (SIT)
Study: 26159147
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment, n=44)
Study: 11737046
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (IVIG) therapy
Study: 8509627
Drug: Recombinant interferon‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon‐alpha 2a (6 MU, thrice weekly)
Study: 8509627
Drug: Recombinant or
Normalized name: ORE-1001
DrugBank: ORE-1001 (DB12271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant or natural interferon‐alpha (3 MU, thrice weekly)
Study: 8509627
Drug: 12-month schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month schedule of interferon administration
Study: 29792885
Drug: 20 IU
Normalized name: Calcium/Phosphorus/Vitamin D 105 MG-81 MG-120 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU intranasal vasopressin
Study: 27458307
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus ipilimumab (10 mg/kg every 3 weeks for a total of four doses)
Study: 27458307
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus ipilimumab (10 mg/kg)
Study: 18287163
Drug: O-(beta-hydroxyethyl)-rutosides (HR)
Normalized name: Padimate O
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: O-(beta-hydroxyethyl)-rutosides (HR) 1500 mg/d
Study: 18287163
Drug: O-(beta-hydroxyethyl)-rutosides (HR)
Normalized name: Padimate O
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: O-(beta-hydroxyethyl)-rutosides (HR) 2 g/d
Study: 18287163
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no pharmacologic or compression treatment)